Since lysoplasmalogenase is immediately upstream of FALDH, and PLA2G12A and PLA2G16 are immediately upstream of lysoplasmalogenase in the degradation pathway of ether phospholipids, decreased expressions of these enzymes could have contributed to an increased level of ether phospholipids in the cells established from the SLS patients. The gene discussed is PLAAT3; the disease is Sjogren-Larsson syndrome.